Inhibition of bacterial biofilms by the snake venom proteome

Q1 Immunology and Microbiology

Biotechnology Reports Pub Date : 2023-09-01 DOI:10.1016/j.btre.2023.e00810

Neyaz A. Khan , Fernanda G. Amorim , John P. Dunbar , Dayle Leonard , Damien Redureau , Loïc Quinton , Michel M. Dugon , Aoife Boyd

{"title":"Inhibition of bacterial biofilms by the snake venom proteome","authors":"Neyaz A. Khan , Fernanda G. Amorim , John P. Dunbar , Dayle Leonard , Damien Redureau , Loïc Quinton , Michel M. Dugon , Aoife Boyd","doi":"10.1016/j.btre.2023.e00810","DOIUrl":null,"url":null,"abstract":"<div>Snake venoms possess a range of pharmacological and toxicological activities. Here we evaluated the antibacterial and anti-biofilm activity against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) of venoms from the Samar spitting cobra Naja samarensis and the Puff adder Bitis arietans. Both venoms prevented biofilm production by pathogenic S. aureus in a growth-independent manner, with the B. arietans venom being most potent. Fractionation showed the active molecule to be heat-labile and >10 kDa in size. Proteomic profiles of N. samarensis venom revealed neurotoxins and cytotoxins, as well as an abundance of serine proteases and three-finger toxins, while serine proteases, metalloproteinases and C-lectin types were abundant in B. arietans venom. These enzymes may have evolved to prevent bacteria colonising the snake venom gland. From a biomedical biotechnology perspective, they have valuable potential for anti-virulence therapy to fight antibiotic resistant microbes.</div>","PeriodicalId":38117,"journal":{"name":"Biotechnology Reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407894/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215017X23000309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 1

Abstract

Snake venoms possess a range of pharmacological and toxicological activities. Here we evaluated the antibacterial and anti-biofilm activity against methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA) of venoms from the Samar spitting cobra Naja samarensis and the Puff adder Bitis arietans. Both venoms prevented biofilm production by pathogenic S. aureus in a growth-independent manner, with the B. arietans venom being most potent. Fractionation showed the active molecule to be heat-labile and >10 kDa in size. Proteomic profiles of N. samarensis venom revealed neurotoxins and cytotoxins, as well as an abundance of serine proteases and three-finger toxins, while serine proteases, metalloproteinases and C-lectin types were abundant in B. arietans venom. These enzymes may have evolved to prevent bacteria colonising the snake venom gland. From a biomedical biotechnology perspective, they have valuable potential for anti-virulence therapy to fight antibiotic resistant microbes.

Abstract Image

查看原文本刊更多论文

蛇毒蛋白质组对细菌生物膜的抑制作用

蛇毒具有一系列药理和毒理学活性。在这里，我们评估了吐眼镜蛇和蟾蜍Bitis arietans的毒液对甲氧西林敏感和耐甲氧西林金黄色葡萄球菌（MSSA和MRSA）的抗菌和抗生物膜活性。这两种毒液都以一种与生长无关的方式阻止了致病性金黄色葡萄球菌产生生物膜，其中假种杆菌毒液的效力最强。分级显示活性分子是热不稳定的，并且>；10kDa大小。N.samarensis毒液的蛋白质组学图谱显示神经毒素和细胞毒素，以及丰富的丝氨酸蛋白酶和三指毒素，而丝氨酸蛋白酶、金属蛋白酶和C-凝集素类型在B.arietans毒液中丰富。这些酶的进化可能是为了防止细菌在蛇毒腺中定居。从生物医学生物技术的角度来看，它们具有对抗抗生素耐药性微生物的抗毒力治疗的宝贵潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Reports Immunology and Microbiology-Applied Microbiology and Biotechnology

CiteScore

15.80

自引率

0.00%

发文量

审稿时长

55 days

期刊介绍： Biotechnology Reports covers all aspects of Biotechnology particularly those reports that are useful and informative and that will be of value to other researchers in related fields. Biotechnology Reports loves ground breaking science, but will also accept good science that can be of use to the biotechnology community. The journal maintains a high quality peer review where submissions are considered on the basis of scientific validity and technical quality. Acceptable paper types are research articles (short or full communications), methods, mini-reviews, and commentaries in the following areas: Healthcare and pharmaceutical biotechnology Agricultural and food biotechnology Environmental biotechnology Molecular biology, cell and tissue engineering and synthetic biology Industrial biotechnology, biofuels and bioenergy Nanobiotechnology Bioinformatics & systems biology New processes and products in biotechnology, bioprocess engineering.